Cipla

Cipla Ltd.
Mumbai Central
Mumbai 400 008

29th May 2013

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBERG
Societe Anonyme
11, av de la Porte-Neuve,
L-2227 Luxemberg

Dear Sir,

We are enclosing copy of the Audited Financial Results (Standalone and Consolidated) for the year ended 31st March, 2013 as required under Clause 41 of the Listing Agreement.

It has been approved at the meeting of the Board of Directors of the Company held today at the Registered Office at 3.00 p.m.

Thank you,

Yours faithfully,
For Cipla Limited

M. A. Sanghvi

Mital Sanghvi
Company Secretary

Encl: as above

cc: (1) Central Depository Services (India) Ltd.
16th - 17th Floor, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400 023

(2) National Securities Depository Ltd.
Trade World, 4th Floor, Kamala Mills Compound,
Senapati Bapat Marg, Lower Parel, Mumbai 400 013

Cipla

Cipla Limited
Regd. Office:
Mumbai Central
Mumbai 400 008

STATEMENT OF STANDALONE AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2013

(₹ in crores)

Particulars	Quarter Ended			Year Ended	
	31.03.2013	31.12.2012	31.03.2012	31.03.2013	31.03.2012
	Audited	Unaudited	Audited	Audited	Audited
1. Income from operations					
a) Net Sales/Income from Operations (Net of excise duty)	**1906.21**	2030.70	1814.05	**8015.37**	6807.68
b) Other Operating Income	**60.48**	39.79	51.53	**187.05**	169.82
Total income from operations (net)	**1966.69**	2070.49	1865.58	**8202.42**	6977.50
2. Expenses					
a) Cost of materials consumed	**700.42**	740.03	589.44	**2646.83**	2300.85
b) Purchases of stock-in-trade	**93.46**	277.77	138.17	**706.89**	555.55
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	**(49.49)**	(220.24)	44.87	**(290.75)**	11.24
d) Employee benefits expense	**255.07**	258.60	182.02	**969.28**	728.21
e) Depreciation and amortisation expense	**78.25**	78.00	70.46	**303.03**	282.07
f) Other expenses	**557.78**	521.44	512.30	**2051.03**	1799.79
Total expenses	**1635.49**	1655.60	1537.26	**6386.31**	5677.71
3. Profit (+)/Loss (-) from operations before other income and finance costs (1-2)	**331.20**	414.89	328.32	**1816.11**	1299.79
4. Other Income	**58.45**	53.48	38.96	**229.13**	148.30
5. Profit (+)/Loss (-) before finance costs (3+4)	**389.65**	468.37	367.28	**2045.24**	1448.09
6. Finance costs	**17.63**	9.30	2.26	**33.38**	26.63
7. Profit (+)/Loss (-) before tax (5-6)	**372.02**	459.07	365.02	**2011.86**	1421.46
8. Tax expense	**104.46**	120.29	73.28	**504.75**	297.50
9. Net Profit (+)/Loss (-) after tax (7-8)	**267.56**	338.78	291.74	**1507.11**	1123.96
10. Paid-up equity share capital (Face Value ₹2 per share)	**160.58**	160.58	160.58	**160.58**	160.58
11. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				**8699.97**	7380.73
12. Basic and Diluted Earnings per share (₹) *Not Annualised	***3.33**	*4.22	*3.63	**18.77**	14.00
A. PARTICULARS OF SHAREHOLDING					
1. Public shareholding					
- Number of shares	**500983877**	502473341	506720722	**500983877**	506720722
- Percentage of shareholding	**62.40**	62.58	63.11	**62.40**	63.11
2. Promoters and Promoter Group Shareholding					
a) Pledged/Encumbered					
- Number of shares	**NIL**	NIL	NIL	**NIL**	NIL
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	**NIL**	NIL	NIL	**NIL**	NIL
- Percentage of shares (as a % of the total share capital of the company)	**NIL**	NIL	NIL	**NIL**	NIL
b) Non-Encumbered					
- Number of shares	**295485978**	295485978	295485978	**295485978**	295485978
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	**100.00**	100.00	100.00	**100.00**	100.00
- Percentage of shares (as a % of the total share capital of the company)	**36.80**	36.80	36.80	**36.80**	36.80

Cipla

Particulars	Quarter Ended 31.03.2013
B. INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NIL
Received during the quarter	15
Disposed of during the quarter	15
Remaining unresolved at the end of the quarter	NIL

Notes:

1. The Company is essentially in the pharmaceutical business segment.
2. The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the relevant financial year.
3. The Directors at their meeting held today recommended payment of dividend of ₹ 2 per equity share (face value ₹2) for the year 2012-2013 amounting to ₹ 160.58 crores.
4. In 2003, the Company received notice of demand from the National Pharmaceutical Pricing Authority, Government of India on account of alleged overcharging in respect of certain drugs under the Drug Price Control Order. This was contested before the jurisdictional High Courts in Mumbai, Karnataka and Allahabad wherein it was held in favour of the Company. The orders of Hon'ble High Court of Allahabad and Bombay were challenged before the Hon'ble Supreme Court of India by the Government. Although in the challenge to the decision of the Hon'ble Bombay High Court, the Hon'ble Supreme Court of India restored the matter to the Hon'ble Bombay High Court in August 2003 for interpreting the Drug Policy on the basis of directions and principles laid down by them and the same was pending, in the challenge to the Hon'ble High Court of Allahabad's order, in Feb 2013, the Hon'ble Supreme Court of India transferred the Bombay High Court petition also before itself for a final hearing on both the matters. In an earlier order, the Hon'ble Supreme Court has already restrained the government from taking any coercive action against the company. The Company has been legally advised that on the basis of these orders there is no probability of demand crystallising. Hence no provision is considered necessary in respect of notice of demand aggregating to Rs.1654.92 crores (inclusive of principal amount for the period July 1995 to April 2009 and interest upto January 2012).
5. On 15th May 2013 the shareholders of Cipla Medpro South Africa Limited ("Medpro"), a company incorporated in the Republic of South Africa and listed on JSE Limited, have approved the Scheme of Arrangement ("Scheme") for the Company to acquire 100% of the ordinary share capital of Medpro at a price of ZAR 10 per share, and to settle all outstanding options to acquire Medpro shares . Based on Medpro's current shares and share options outstanding, the total consideration payable would be approximately ZAR 4518 million (approximately Rs. 2666 crores). Medpro is a distributor of Company's products in South Africa and certain neighbouring countries. Implementation of the Scheme is still subject to regulatory and other approvals and conditions.
6. The figures of the previous year have been regrouped/recast to render them comparable with the figures of the current year.
7. The Audited Standalone Statement of assets and liabilities is as under:

(₹ in crores)

Particulars	Year ended	
	31.03.2013	31.03.2012
A. EQUITY AND LIABILITIES		
1. Shareholders' fund		
(a) Share capital	160.58	160.58
(b) Reserves and surplus	8708.94	7389.70
Shareholder's fund	8869.52	7550.28
2. Non-current liabilities		
(a) Long-term borrowings	0.55	2.20
(b) Deferred tax liabilities (net)	281.20	232.45
(c) Other long-term liabilities	30.00	30.00
(d) Long-term provisions	47.34	29.12
Non-current liabilities	359.09	293.77
3. Current liabilities		
(a) Short-term borrowings	965.26	10.00
(b) Trade payables	827.09	685.85
(c) Other current liabilities	242.62	232.79
(d) Short-term provisions	229.63	220.64
Current liabilities	2264.60	1149.28
Total	11493.21	8993.33

B. ASSETS		
1. Non- current assets		
(a) Fixed assets	**3418.29**	3002.66
(b) Capital Work-in-Progress- Tangible	**339.99**	343.45
(c) Intangible Asset under Development	**10.35**	-
(d) Non-current investments	**514.36**	461.83
(e) Long-term loans and advances	**373.72**	393.50
(f) Other non-current assets	**0.31**	0.24
Non- current assets	**4657.02**	4201.68
2. Current assets		
(a) Current investments	**2087.46**	573.32
(b) Inventories	**2343.37**	1824.50
(c) Trade receivables	**1645.22**	1519.31
(d) Cash and cash equivalents	**105.07**	55.06
(e) Short-term loans and advances	**652.79**	765.48
(f) Other current assets	**2.28**	53.98
Current assets	**6836.19**	4791.65
Total	**11493.21**	8993.33

8. The above results after being reviewed by the Audit Committee were approved at the meeting of the Board of Directors held on 29th May, 2013.

By order of the Board
For **CIPLA LIMITED**

M. K. Hamied
Managing Director

Mumbai
29th May, 2013

Cipla Limited
Regd. Office:
Mumbai Central
Mumbai 400 008

Cipla

STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE YEAR ENDED 31ST MARCH, 2013

(₹ in crores)

Particulars	Year Ended	
	31.03.2013	31.03.2012
1. Income from operations		
a) Net sales/Income from operations (Net of excise duty)	8086.82	6847.70
b) Other operating income	192.51	173.01
Total income from operations (net)	8279.33	7020.71
2. Expenses		
a) Cost of materials consumed	2728.92	2326.35
b) Purchases of stock-in-trade	514.30	407.30
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(290.60)	5.65
d) Employee benefits expense	1036.26	772.50
e) Depreciation and amortisation expense	330.48	312.22
f) Other expenses	2092.60	1850.06
Total expenses	6411.96	5674.08
3. Profit (+)/Loss (-) from operations before other income and finance costs (1-2)	1867.37	1346.63
4. Other income	222.14	139.52
5. Profit (+)/Loss (-) before finance costs (3+4)	2089.51	1486.15
6. Finance costs	33.91	38.34
7. Profit (+)/Loss (-) before Exceptional Items and tax (5-6)	2055.60	1447.81
8. Exceptional Item	39.77	-
9. Profit (+)/Loss (-) before tax (7+8)	2095.37	1447.81
10. Tax expense	544.31	306.51
11. Net Profit (+)/Loss (-) after tax (9-10)	1551.06	1141.30
12. Share of Profit (+) / Loss (-) of associates	(6.21)	2.94
13. Net Profit (+) / Loss (-) for the period (11+12)	1544.85	1144.24
14. Paid-up equity share capital (Face Value ₹2 per share)	160.58	160.58
15. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	8849.13	7469.38
16. Basic and diluted earnings per share (₹)	19.24	14.25

Particulars	Year Ended	
	31.03.2013	31.03.2012
PARTICULARS OF SHAREHOLDING		
1. **Public shareholding**		
- Number of shares	**500983877**	506720722
- Percentage of shareholding	**62.40**	63.11
2. **Promoters and Promoter Group Shareholding**		
a) Pledged/Encumbered		
- Number of shares	**NIL**	NIL
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	**NIL**	NIL
- Percentage of shares (as a % of the total share capital of the company)	**NIL**	NIL
b) Non-Encumbered		
- Number of shares	**295485978**	295485978
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	**100.00**	100.00
- Percentage of shares (as a % of the total share capital of the company)	**36.80**	36.80

Notes:

1. The Company is essentially in the pharmaceutical business segment.
2. The Directors at their meeting held today recommended payment of dividend of ₹ 2 per equity share (face value ₹2) for the year 2012-2013 amounting to ₹ 160.58 crores.
3. The consolidated accounts have been prepared in accordance with the principles set out in Accounting Standard 21 - Consolidated Financial Statements , Accounting Standard 23 - Accounting for Investments in Associates and Accounting Standard 27 – Financial Reporting in Joint Ventures in Consolidated Financial Statements notified in the Companies (Accounting Standard) Rules 2006. The financial results of associates and joint venture have been included in the consolidated results on the basis of management accounts not reviewed by the auditors.
4. Exceptional Item represents profit on sale of investment in Desano Holdings Ltd by subsidiaries.
5. In 2003, the Company received notice of demand from the National Pharmaceutical Pricing Authority, Government of India on account of alleged overcharging in respect of certain drugs under the Drug Price Control Order. This was contested before the jurisdictional High Courts in Mumbai, Karnataka and Allahabad wherein it was held in favour of the Company. The orders of Hon'ble High Court of Allahabad and Bombay were challenged before the Hon'ble Supreme Court of India by the Government. Although in the challenge to the decision of the Hon'ble Bombay High Court, the Hon'ble Supreme Court of India restored the matter to the Hon'ble Bombay High Court in August 2003 for interpreting the Drug Policy on the basis of directions and principles laid down by them and the same was pending, in the challenge to the Hon'ble High Court of Allahabad's order, in Feb 2013, the Hon'ble Supreme Court of India transferred the Bombay High Court petition also before itself for a final hearing on both the matters. In an earlier order, the Hon'ble Supreme Court has already restrained the government from taking any coercive action against the company. The Company has been legally advised that on the basis of these orders there is no probability of demand crystallising. Hence no provision is considered necessary in respect of notice of demand aggregating to Rs.1654.92 crores (inclusive of principal amount for the period July 1995 to April 2009 and interest upto January 2012).
6. On 15th May 2013 the shareholders of Cipla Medpro South Africa Limited ("Medpro"), a company incorporated in the Republic of South Africa and listed on JSE Limited, have approved the Scheme of Arrangement ("Scheme") for the Company to acquire 100% of the ordinary share capital of Medpro at a price of ZAR 10 per share, and to settle all outstanding options to acquire Medpro shares . Based on Medpro's current shares and share options outstanding, the total consideration payable would be approximately ZAR 4518 million (approximately Rs. 2666 crores). Medpro is a distributor of Company's products in South Africa and certain neighbouring countries. Implementation of the Scheme is still subject to regulatory and other approvals and conditions.
7. The Audited Standalone financial results is available on the Company's website i.e. www.cipla.com. The key standalone financial information for the year 2012-2013 are as under:
   a. Total income from operations (net): ₹8202.42 crore (previous year ₹6977.50 crore)
   b. Profit before tax: ₹2011.86 crore (previous year ₹1421.46 crore)
   c. Profit after tax: ₹1507.11 crore (previous year ₹1123.96 crore)
8. The figures of the previous year have been regrouped/recast to render them comparable with the figures of the current year.

9. The Audited Consolidated Statement of assets and liabilities is as under:

(₹ in crores)

Particulars	Year ended	
	31.03.2013	31.03.2012
A. EQUITY AND LIABILITIES		
1. Shareholders' fund		
(a) Share capital	160.58	160.58
(b) Reserves and surplus	8858.10	7478.35
Shareholders' fund	9018.68	7638.93
2. Non-current liabilities		
(a) Long-term borrowings	0.55	3.25
(b) Deferred tax liabilities (net)	280.54	233.24
(c) Other long-term liabilities	30.00	30.00
(d) Long-term provisions	50.37	31.17
Non-current liabilities	361.46	297.66
3. Current liabilities		
(a) Short-term borrowings	966.38	10.20
(b) Trade payables	828.36	691.77
(c) Other current liabilities	250.89	489.93
(d) Short-term provisions	232.00	221.29
Current liabilities	2277.63	1413.19
Total	11657.77	9349.78
B. ASSETS		
1. Non- current assets		
(a) Fixed assets	3609.97	3215.49
(b) Capital Work-in-Progress- Tangible	367.44	371.17
(c) Intangible Asset under Development	10.35	-
(d) Non-current investments	415.69	328.59
(e) Long-term loans and advances	357.80	372.35
(f) Other non-current assets	5.11	5.37
Non- current assets	4766.36	4292.97
2. Current assets		
(a) Current investments	2116.75	940.52
(b) Inventories	2387.07	1850.08
(c) Trade receivables	1668.84	1553.58
(d) Cash and cash equivalents	143.01	90.46
(e) Short-term loans and advances	573.46	568.19
(f) Other current assets	2.28	53.98
Current assets	6891.41	5056.81
Total	11657.77	9349.78

10. The above results after being reviewed by the Audit Committee were approved at the meeting of the Board of Directors held on 29th May,2013.

By order of the Board
For **CIPLA LIMITED**

M. K. Hamied
Managing Director

Mumbai
29th May, 2013